ICANS

Clinical trials for ICANS explained in plain language.

Never miss a new study

Get alerted when new ICANS trials appear

Sign up with your email to follow new studies for ICANS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1 Completed 1

New drug may tame Life-Threatening side effects of cancer immunotherapy

Disease control Completed

This study tested whether the drug siltuximab can lessen the severity of cytokine release syndrome (CRS) and neurological side effects (ICANS) that often occur after CAR-T cell therapy for blood cancers like lymphoma and leukemia. Twenty-four participants received siltuximab alon…

Matched conditions: ICANS

Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control

Last updated Jun 27, 2026 13:01 UTC

ICANS

Get alerted when new ICANS trials appear

New drug may tame Life-Threatening side effects of cancer immunotherapy